<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817751</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14816</org_study_id>
    <secondary_id>HM14816</secondary_id>
    <secondary_id>NCI-2013-00705</secondary_id>
    <secondary_id>P30CA016059</secondary_id>
    <nct_id>NCT01817751</nct_id>
  </id_info>
  <brief_title>Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma</brief_title>
  <official_title>Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety, tolerability, and effectiveness of&#xD;
      the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and&#xD;
      sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-center, open-label phase 2 study, with an early stopping rule in place&#xD;
      for safety. The trial will include patients with recurrent or progressive high-grade glioma.&#xD;
&#xD;
      The trial will be conducted in an adaptive design, with a Simon's mini-max 2-stage design&#xD;
      incorporating an interim analysis for efficacy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 11, 2013</start_date>
  <completion_date type="Anticipated">October 30, 2027</completion_date>
  <primary_completion_date type="Actual">August 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 6-Month Progression Free Survival (PFS)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of patients evaluable for response, regardless of tumor platelet derived growth factor receptor (PDGFR) status, with 6- month PFS defined as the time from the first day a patient receives study treatment until time of progression per response assessment in neuro-oncology (RANO) or Macdonald criteria or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Whose Tumors Express PDGFRa With and Without 6-Month PFS.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of patients evaluable for response, with tumors that express PDGFRα, with 6-month PFS defined as the time from the first day a patient receives study treatment until time of progression per RANO or Macdonald criteria or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Best Response of CR Plus Number of Participants With Best Response of PR.</measure>
    <time_frame>From the first day of study treatment until best response or off study, up to 4 years</time_frame>
    <description>Overall response rate (CR+PR), using RANO or Macdonald criteria, in patients evaluable for response regardless of tumor PDGFR status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Whose Tumors Express PDGFRa With Best Response of CR Plus Number of Participants Whose Tumor Expresses PDGFRa With Best Response of PR.</measure>
    <time_frame>From initiation of study treatment to time of best response or off-study (up to 4 years)</time_frame>
    <description>Overall response rate (CR+PR), using RANO or Macdonald criteria, in patients who are evaluable for response and who have tumors that express PDGFRα.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 12-Month Progression Free Survival (PFS).</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number of patients evaluable for response, regardless of tumor PDGFR status, who are alive at 12 months after the first day a patient receives study treatment. Overall Survival (OS) defined as the time from the first day a patient receives study treatment until death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Whose Tumors Express PDGFRa With and Without 12-Month PFS.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Proportion of patients evaluable for response with tumors that express PDGFRα who are alive at 12 months after the first day a patient receives study treatment. On study is defined as the time from the first day a patient receives study treatment until death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety and Toxicity of Sorafenib, Valproic Acid, and Sildenafil</measure>
    <time_frame>From initiation of study therapy to completion of adverse event (AE) observation period, up to 30 days following the end of study treatment.</time_frame>
    <description>Number of patients with adverse events, and types of events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Recurrent Adult Brain Neoplasm</condition>
  <condition>Malignant Glioma</condition>
  <condition>WHO Grade III Glioma</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate, valproic acid, sildenafil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Treatment (sorafenib tosylate, valproic acid, sildenafil)</arm_group_label>
    <other_name>pyridinecarboxamide, chloro-trifluoromethylphenyl pyridine-carboxylic acid methylamide-methylbenzenesulfonate tosylate, Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Treatment (sorafenib tosylate, valproic acid, sildenafil)</arm_group_label>
    <other_name>2-Propylpentanoic or Propylvaleric Acid, Alti-Valproic, Depakene, Di-n-propylacetic Acid, Ergenyl, Novo-Valproic, VA, Valproate, Valproate Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Treatment (sorafenib tosylate, valproic acid, sildenafil)</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed high-grade glioma (World Health Organization (WHO) grade 3 or&#xD;
             4), with documented computed tomography (CT) or magnetic resonance imaging (MRI)&#xD;
             progression or recurrence. Biopsy is also an acceptable method of confirming&#xD;
             progression or recurrence. If initial tumor was grade 2 glioma, histological&#xD;
             confirmation of high-grade recurrence is required&#xD;
&#xD;
               -  After first interim analysis, if the study proceeds to enrollment of selected&#xD;
                  patients (only those who have platelet-derived growth factor receptor&#xD;
                  (PDGFRa)-positive tumors), patients will be pre-registered for PDGFRa analysis&#xD;
                  and registered to the combination treatment schema only if PDGFRa-positive an all&#xD;
                  other enrollment criteria are met.&#xD;
&#xD;
          -  Measurable or evaluable disease by response assessment in neuro-oncology (RANO) (MRI)&#xD;
             or MacDonald (CT) criteria&#xD;
&#xD;
          -  Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1&#xD;
             week prior to cycle 1 day 1.&#xD;
&#xD;
          -  At least 12 weeks since the completion of radiation therapy to a total of &gt;=50 Gray&#xD;
             (Gy).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  White blood cell (WBC) &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 8.5 g/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =&lt; 3 x upper limit of&#xD;
             normal (ULN) for the laboratory&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN for the laboratory (total bilirubin criteria may be&#xD;
             waived if a patient has documented Gilbert's disease)&#xD;
&#xD;
          -  Creatinine clearance (CrCL) &gt;= 30 mL/min as calculated by standard Cockcroft-Gault&#xD;
             equation&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of treatment.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use a medically accepted form of&#xD;
             birth control for the duration of study participation and for 2 months following&#xD;
             completion of study treatment.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigational agent within 4 weeks of first dose of study treatment&#xD;
&#xD;
          -  Prior bevacizumab or tyrosine-kinase inhibitor&#xD;
&#xD;
          -  History of allergic reactions or intolerance to any of the required agents on the&#xD;
             study&#xD;
&#xD;
          -  Any condition that would prohibit patient from initiating valproic acid. Current or&#xD;
             prior valproic acid treatment is allowed (do not need to be ≥ LLN for laboratory for&#xD;
             enrollment).&#xD;
&#xD;
          -  Seizure disorder necessitating the use of enzyme-inducing antiepileptic drugs&#xD;
             (EIAEDs). Efforts may be made by the treating physician to change the antiepileptic&#xD;
             drug from another agent to valproic acid or non-EIAED prior to excluding the patient&#xD;
             from study&#xD;
&#xD;
          -  Contraindication to antiangiogenic agents, including:&#xD;
&#xD;
               -  Bronchopulmonary hemorrhage/bleeding event &gt;= grade 2 (NCI Common Terminology&#xD;
                  Criteria for Adverse Events [CTCAE] version 4.0) within 4 weeks or less prior to&#xD;
                  first dose of study drug&#xD;
&#xD;
               -  Any other hemorrhage/bleeding event &gt;= grade 3 (NCI CTCAE v4.0) within 4 weeks or&#xD;
                  less prior to first dose of study treatment&#xD;
&#xD;
               -  Radiological evidence of any intracranial hemorrhage within the 4 weeks or less&#xD;
                  less prior to first dose of study treatment&#xD;
&#xD;
               -  History of significant intratumoral, intracerebral, or subarachnoid hemorrhage&#xD;
&#xD;
               -  Serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  Documented bowel perforation within 6 months of the start of study treatment.&#xD;
&#xD;
          -  Major surgery within 2 weeks of the start of study treatment, or ongoing complications&#xD;
             from surgeries performed previously&#xD;
&#xD;
          -  Clinically significant cardiac disease, including major cardiac dysfunction, such as&#xD;
             uncontrolled angina, clinical congestive heart failure with New York Heart Association&#xD;
             (NYHA) class III or higher, ventricular arrhythmias requiring antiarrhythmic therapy,&#xD;
             recent (within 6 months) myocardial infarction or unstable coronary artery disease.&#xD;
&#xD;
          -  Systolic blood pressure (BP) &gt; 160 mm Hg or diastolic pressure &gt; 100 mm Hg despite&#xD;
             optimal medical management&#xD;
&#xD;
          -  History of priapism&#xD;
&#xD;
          -  Known history of retinitis pigmentosa&#xD;
&#xD;
          -  Known mitochondrial disorder caused by mutations in mitochondrial DNA polymerase γ.&#xD;
&#xD;
          -  Arterial thromboembolic or embolic events such as myocardial infarction,&#xD;
             cerebrovascular accident, including transient ischemic attacks 6 months prior to first&#xD;
             study treatment&#xD;
&#xD;
          -  Serious uncontrolled infection &gt; grade 2 (CTCAE v 4)&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positivity&#xD;
&#xD;
          -  Unable to swallow medication or suspected malabsorption&#xD;
&#xD;
          -  Patients on chronic nitrate therapy or alpha-blockers&#xD;
&#xD;
             * Exclude persons who require ongoing administration of STRONG CYP3A4 inhibitors&#xD;
             and/or STRONG CYP3A4 inducers and/or STRONG CYP2C9 inhibitors.&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Persistent heart rate (HR) &lt;50 or &gt;120 beats per minute (bpm)&#xD;
&#xD;
          -  Corrected QT (QTc) &gt; 480 ms (grade 2 or greater) on screening electrocardiogram (ECG)&#xD;
&#xD;
             * If baseline QTc on screening ECG meets exclusion criteria on screening assessment:&#xD;
&#xD;
               -  Check potassium and magnesium levels&#xD;
&#xD;
               -  Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to&#xD;
                  confirm exclusion of patient due to QTc&#xD;
&#xD;
               -  For patients with a heart rate (HR) 60-100 bpm, no manual read of QT is required&#xD;
&#xD;
               -  For patients with baseline HR &lt; 60 or &gt; 100 bpm, manual read of QT by&#xD;
                  cardiologist is required using Fridericia correction&#xD;
&#xD;
          -  Other condition(s) that in the opinion of the investigator might compromise the&#xD;
             objectives of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark G Malkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <results_first_submitted>August 17, 2021</results_first_submitted>
  <results_first_submitted_qc>October 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2021</results_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central nervous system</keyword>
  <keyword>Brain and Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT01817751/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT01817751/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
          <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
          <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 6-Month Progression Free Survival (PFS)</title>
        <description>Number of patients evaluable for response, regardless of tumor platelet derived growth factor receptor (PDGFR) status, with 6- month PFS defined as the time from the first day a patient receives study treatment until time of progression per response assessment in neuro-oncology (RANO) or Macdonald criteria or death, whichever occurs first.</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
            <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 6-Month Progression Free Survival (PFS)</title>
          <description>Number of patients evaluable for response, regardless of tumor platelet derived growth factor receptor (PDGFR) status, with 6- month PFS defined as the time from the first day a patient receives study treatment until time of progression per response assessment in neuro-oncology (RANO) or Macdonald criteria or death, whichever occurs first.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Met 6 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not meet 6 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Whose Tumors Express PDGFRa With and Without 6-Month PFS.</title>
        <description>Number of patients evaluable for response, with tumors that express PDGFRα, with 6-month PFS defined as the time from the first day a patient receives study treatment until time of progression per RANO or Macdonald criteria or death, whichever occurs first.</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
            <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Whose Tumors Express PDGFRa With and Without 6-Month PFS.</title>
          <description>Number of patients evaluable for response, with tumors that express PDGFRα, with 6-month PFS defined as the time from the first day a patient receives study treatment until time of progression per RANO or Macdonald criteria or death, whichever occurs first.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Met 6 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not meet 6 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Best Response of CR Plus Number of Participants With Best Response of PR.</title>
        <description>Overall response rate (CR+PR), using RANO or Macdonald criteria, in patients evaluable for response regardless of tumor PDGFR status</description>
        <time_frame>From the first day of study treatment until best response or off study, up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
            <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Best Response of CR Plus Number of Participants With Best Response of PR.</title>
          <description>Overall response rate (CR+PR), using RANO or Macdonald criteria, in patients evaluable for response regardless of tumor PDGFR status</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># Pts with best response of CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Pts with best response of PR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Pts without best response of PR or CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Pts not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Whose Tumors Express PDGFRa With Best Response of CR Plus Number of Participants Whose Tumor Expresses PDGFRa With Best Response of PR.</title>
        <description>Overall response rate (CR+PR), using RANO or Macdonald criteria, in patients who are evaluable for response and who have tumors that express PDGFRα.</description>
        <time_frame>From initiation of study treatment to time of best response or off-study (up to 4 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
            <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Whose Tumors Express PDGFRa With Best Response of CR Plus Number of Participants Whose Tumor Expresses PDGFRa With Best Response of PR.</title>
          <description>Overall response rate (CR+PR), using RANO or Macdonald criteria, in patients who are evaluable for response and who have tumors that express PDGFRα.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># Pts with best response of CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Pts with best response of PR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Pts without best response of PR or CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Pts not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 12-Month Progression Free Survival (PFS).</title>
        <description>Number of patients evaluable for response, regardless of tumor PDGFR status, who are alive at 12 months after the first day a patient receives study treatment. Overall Survival (OS) defined as the time from the first day a patient receives study treatment until death by any cause.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
            <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 12-Month Progression Free Survival (PFS).</title>
          <description>Number of patients evaluable for response, regardless of tumor PDGFR status, who are alive at 12 months after the first day a patient receives study treatment. Overall Survival (OS) defined as the time from the first day a patient receives study treatment until death by any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># That met 12 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title># That did not meet 12 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Whose Tumors Express PDGFRa With and Without 12-Month PFS.</title>
        <description>Proportion of patients evaluable for response with tumors that express PDGFRα who are alive at 12 months after the first day a patient receives study treatment. On study is defined as the time from the first day a patient receives study treatment until death by any cause.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
            <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Whose Tumors Express PDGFRa With and Without 12-Month PFS.</title>
          <description>Proportion of patients evaluable for response with tumors that express PDGFRα who are alive at 12 months after the first day a patient receives study treatment. On study is defined as the time from the first day a patient receives study treatment until death by any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># That met 12 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title># That did not meet 12 month PFS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title># Not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Safety and Toxicity of Sorafenib, Valproic Acid, and Sildenafil</title>
        <description>Number of patients with adverse events, and types of events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).</description>
        <time_frame>From initiation of study therapy to completion of adverse event (AE) observation period, up to 30 days following the end of study treatment.</time_frame>
        <posting_date>10/2027</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From initiation of study therapy to completion of adverse event (AE) observation period, up to 30 days following the end of study treatment up to 7 years.</time_frame>
      <desc>Number of patients with adverse events, and types of events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil)</title>
          <description>Sorafenib 400 mg orally twice a day;&#xD;
Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;&#xD;
Sildenafil 50 mg orally twice a day&#xD;
A cycle consists of 4 weeks.&#xD;
*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)&#xD;
sorafenib tosylate: Given by mouth&#xD;
valproic acid: Given by mouth&#xD;
sildenafil citrate: Given by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Colonic Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ileal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>gait disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>general disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>edema Limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="47" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="47" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>investigations-other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>muscle weakness, right-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>concentration impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysphasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>renal calculi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>social circumstances-other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cardiac disorders-other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>sinus bradycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>sinus tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear and labyrinth disorders-other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hearing impaired</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>cushingoid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>endocrine disorders-other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>eye disorders-other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>watering eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fecal incontinence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>oral dysesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>oral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>gait disturbance</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>edema limbs</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>infections and infestations-other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>mucosal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>papulopustular rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>prostate infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>skin infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>soft tissue infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>injury, poisoning and procedural complications- other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>blood bilirubin increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cholesterol high</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>investigations - other, specify</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="22" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="32" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="22" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>glucose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="26" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="35" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>buttock pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>joint range of motion decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>concentration impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>depressed level of consciousness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysarthria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysphasia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>edema cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>facial muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypersomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>memory impairment</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nervous system disorders- other, specify</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>sinus pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>spasticity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>delusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hallucinations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>personality change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>psychiatric disorders- other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>renal calculi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary incontienence</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary tract pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary urgency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>genital edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>allergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hoarseness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>sleep apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>body odor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="55" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>rash acneiform</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>rash maculo-papular</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>scalp pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>skin and subcutaneous tissue disorders- other, specify</sub_title>
                <counts group_id="E1" events="24" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="44" subjects_affected="19" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Massey Cancer Center CTO Operations Managers</name_or_title>
      <organization>Virginia Commonwealth University Massey Cancer Center</organization>
      <phone>877-4627739</phone>
      <email>ctoclinops@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

